These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Funk M; Kriechbaum K; Prager F; Benesch T; Georgopoulos M; Zlabinger GJ; Schmidt-Erfurth U Invest Ophthalmol Vis Sci; 2009 Mar; 50(3):1025-32. PubMed ID: 19060280 [TBL] [Abstract][Full Text] [Related]
32. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. Yoshimura T; Sonoda KH; Sugahara M; Mochizuki Y; Enaida H; Oshima Y; Ueno A; Hata Y; Yoshida H; Ishibashi T PLoS One; 2009 Dec; 4(12):e8158. PubMed ID: 19997642 [TBL] [Abstract][Full Text] [Related]
33. Retinal vein occlusion and the optic disk. Hayreh SS; Zimmerman MB; Podhajsky PA Retina; 2012; 32(10):2108-18. PubMed ID: 22914682 [TBL] [Abstract][Full Text] [Related]
34. Comprehensive analysis of vitreous chemokines involved in ischemic retinal vein occlusion. Zeng Y; Cao D; Yu H; Zhuang X; Yang D; Hu Y; He M; Zhang L Mol Vis; 2019; 25():756-765. PubMed ID: 31814701 [TBL] [Abstract][Full Text] [Related]
35. High intravitreal TGF-β1 and MMP-9 levels in eyes with retinal vein occlusion. Tuuminen R; Loukovaara S Eye (Lond); 2014 Sep; 28(9):1095-9. PubMed ID: 24946846 [TBL] [Abstract][Full Text] [Related]
36. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Pe'er J; Folberg R; Itin A; Gnessin H; Hemo I; Keshet E Ophthalmology; 1998 Mar; 105(3):412-6. PubMed ID: 9499769 [TBL] [Abstract][Full Text] [Related]
37. [Radial optic neurotomy in ischemic central retinal vein occlusion]. Lerche RC; Richard G Klin Monbl Augenheilkd; 2005 Feb; 222(2):134-41. PubMed ID: 15719318 [TBL] [Abstract][Full Text] [Related]